IP Library Granted Patent US 10,195,273
Granted Patent B2
US 10,195,273 · App. 15/820,296 · Granted Feb 5, 2019

Selectively altering microbiota for immune modulation

Inventor: Jasper Clube (London, GB)
Assignee: SNIPR TECHNOLOGIES LIMITED
A61K39/3955A61K31/7105A61K35/15A61K35/17A61K39/0011A61P35/00A61P37/00A61K2039/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,195,273
App. No.
15/820,296
Granted
Feb 5, 2019
Kind
B2
Abstract

The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.

Claims (11)

1. A method for modulating a therapy of a disease or condition in a human or animal patient, the method comprises altering the relative proportion of a sub-population of gram negative bacteria in a microbiota of the patient by administering a bacterial transplant to the patient, wherein the therapy comprises administration of an effective amount of an immune checkpoint inhibitor to the patient, wherein the immune checkpoint inhibitor is a PD-1 (programmed death-1) inhibitor or a PD-L1 (programmed death-ligand 1) inhibitor, and wherein the bacterial transplant comprises Akkermansia or Faecalibacterium.

2. The method of claim 1 , wherein the immune checkpoint inhibitor is an antibody.

3. The method of claim 2 , wherein the immune checkpoint inhibitor is nivolumab, pembrolizumab, pidilizumab, durvalumab, or atezolizumab.

4. The method of claim 1 , wherein the microbiota is gut microbiota.

5. The method of claim 1 , wherein the bacterial transplant comprises Akkermansia muciniphila or Faecalibacterium prausnitzii.

6. The method of claim 1 , wherein the disease is cancer.

7. The method of claim 6 , wherein the cancer is melanoma, non-small-cell lung cancer (NSCLC), or renal cell carcinoma (RCC).

8. The method of claim 1 , wherein the bacterial transplant comprises Akkermansia.

9. The method of claim 5 , wherein the bacterial transplant comprises Akkermansia muciniphila.

10. The method of claim 1 , wherein the bacterial transplant comprises Faecalibacterium.

11. The method of claim 5 , wherein the bacterial transplant comprises Faecalibacterium prausnitzii.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2018
From: CLUBE, JASPER; SOMMER, MORTEN; GRØNDAHL, CHRISTIAN; VAZQUEZ-URIBE, RUBEN; VAN DER HELM, ERIC
To: SNIPR TECHNOLOGIES LIMITED
Reel/Frame 044875/0541 →
Priority Claims (1)
GB 1609811.3 · Jun 5, 2016 · national
Continuity (2)
Continuation PCTEP2017063593 · Jun 4, 2017
Related Publication 20180140698A1 · May 24, 2018
Cited By (18)
US 12,226,430 US 12,246,043 US 12,257,272 US 12,279,989 US 12,310,995 US 12,318,411 US 12,318,414 US 12,318,445 US 12,329,783 US 12,357,662 US 12,404,513 US 12,448,619 US 12,502,401 US 12,514,867 US 12,514,869 US 12,516,297 US 12,528,842 US 12,533,312